• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  2. Why Retirees Should Consider Investing Abroad

    Readers say diversification and exposure to good companies call for looking beyond the U.S.

  3. Roche Receives FDA Approval for cobas® KRAS Mutation Test

    Roche Receives FDA Approval for cobas® KRAS Mutation Test

  4. Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO

    Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO

  5. A Push-Me, Pull-You Market

    Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...

  6. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

  7. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    These top managers continue to focus on higher-quality dividend-paying stocks in a market that has become more volatile of late.

  8. Complexities of Eye Care Drive Strong Moats

    We see attractive growth opportunities for the ophthalmology market.

  9. Announcing the Morningstar Fund Managers of the Year for 2014

    Success starts with teamwork for this year's winners.

  10. Leader in Genomic Sequencing Illuminates the Way

    Continued technology advancements and market expansion support Illumina's narrow moat.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.